(
EMAILWIRE.COM, August 21, 2018 ) Rubella is an acute, viral, and contagious infection, which has a mild effect on children and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS). Rubella vaccine has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it.
Browse full report @
https://www.marketdataforecast.com/market-reports/north-america-rubella-vaccine-market-6399/North America Rubella Vaccine (Human Diploid Cell) market is anticipated to grow at XX % CAGR from 2018 to 2023 and it is estimated that the North America market was valued at USD XX billion in 2018 and is expected to reach USD XX billion by 2023.
Request sample report @
https://www.marketdataforecast.com/market-reports/north-america-rubella-vaccine-market-6399/request-sampleThe
North America Rubella Vaccine market is segmented on the basis of End User. On the basis of End User, the market is segmented into Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine.
Request discount @
https://www.marketdataforecast.com/market-reports/north-america-rubella-vaccine-market-6399/request-discountOn the basis of geography, the Rubella Vaccine market is segmented into US and Canada. North America accounted for the largest share of the Rubella Vaccine market.
The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).
Buy full report @
https://www.marketdataforecast.com/cart/buy-now/north-america-rubella-vaccine-market-6399
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.comSource:
EmailWire.Com